UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The utility of Martius fat pad in the repair of urogenital fistulae: review of current evidence

BJU international, 2024-09, Vol.134 (3), p.365-374

2024

Volltextzugriff (PDF)

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Volltextzugriff (PDF)

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii147

2018

Volltextzugriff (PDF)

14.1: Invited Paper: Heavy Metal-Free Quantum Dots for Display Applications

SID International Symposium Digest of technical papers, 2015-06, Vol.46 (1), p.168-169

2015

Volltextzugriff (PDF)

Structural Phase Transitions and Superconductivity in Fe1+δSe0.57Te0.43 at Ambient and Elevated Pressures

Journal of the American Chemical Society, 2009-11, Vol.131 (46), p.16944-16952

2009

Volltextzugriff (PDF)

39‐4: Invited Paper: Innovation in Heavy Metal‐Free Quantum Dot Technology

SID International Symposium Digest of technical papers, 2017-05, Vol.48 (1), p.562-564

2017

Volltextzugriff (PDF)

622P Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study

Annals of oncology, 2020-09, Vol.31, p.S514-S514

2020

Volltextzugriff (PDF)

34-1: Invited Paper: Heavy Metal-Free Quantum Dots Making Inroads for Consumer Applications

SID International Symposium Digest of technical papers, 2016-05, Vol.47 (1), p.425-427

2016

Volltextzugriff (PDF)

624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound

Annals of oncology, 2020-09, Vol.31, p.S515-S516

2020

Volltextzugriff (PDF)

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Annals of oncology, 2019-10, Vol.30, p.v477

2019

Volltextzugriff (PDF)

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Volltextzugriff (PDF)

1191O - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Annals of oncology, 2019-10, Vol.30, p.v477-v477

2019

Volltextzugriff (PDF)

610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Annals of oncology, 2020-09, Vol.31, p.S508-S508

2020

Volltextzugriff (PDF)

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-05-03-OT3-05-03

2019

Volltextzugriff (PDF)

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA -mutated (g BRCA m) metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD5-04-PD5-04

2019

Volltextzugriff (PDF)

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Gynecologic oncology, 2018-06, Vol.149, p.246-247

2018

Volltextzugriff (PDF)

206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292

ESMO open, 2023-05, Vol.8 (1), p.101395, Article 101395

2023

Volltextzugriff (PDF)

448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2044-S2045

2017

Volltextzugriff (PDF)

Structural Phase Transitions and Superconductivity in Fe 1+δ Se 0.57 Te 0.43 at Ambient and Elevated Pressures

Journal of the American Chemical Society, 2009-11, Vol.131 (46), p.16944-16952

2009

Volltextzugriff (PDF)

Progress in the Development of Heavy Metal-Free Quantum Dots for Electroluminescent Displays

2018 25th International Workshop on Active-Matrix Flatpanel Displays and Devices (AM-FPD), 2018, p.1-3

2018

Volltextzugriff (PDF)

Structural phase transitions and superconductivity in Fe(1+delta)Se0.57Te0.43 at ambient and elevated pressures

Journal of the American Chemical Society, 2009-11, Vol.131 (46), p.16944-16952

2009

Volltextzugriff (PDF)

Major Threat to Malaria Control Programs by Plasmodium falciparum Lacking Histidine-Rich Protein 2, Eritrea

Emerging infectious diseases, 2018-03, Vol.24 (3), p.462-470

2018

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(54)
Science & Technology
(54)
Life Sciences & Biomedicine
(50)
Adult
(37)
Middle Aged
(31)
Biological And Medical Sciences
(30)
Male
(30)
Female
(29)
Neurosciences & Neurology
(29)
Space Life Sciences
(24)
Neurosciences
(22)
Medical Sciences
(21)
Aged
(16)
Clinical Neurology
(16)
Neurology
(13)
Reflex, Vestibulo-Ocular - Physiology
(10)
Fundamental And Applied Biological Sciences. Psychology
(9)
Otorhinolaryngology
(8)
Eye Movements - Physiology
(7)
Parasites
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The utility of Martius fat pad in the repair of urogenital fistulae: review of current evidence

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

14.1: Invited Paper: Heavy Metal-Free Quantum Dots for Display Applications

Structural Phase Transitions and Superconductivity in Fe1+δSe0.57Te0.43 at Ambient and Elevated Pressures

39‐4: Invited Paper: Innovation in Heavy Metal‐Free Quantum Dot Technology

622P Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study

34-1: Invited Paper: Heavy Metal-Free Quantum Dots Making Inroads for Consumer Applications

624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

1191O - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA -mutated (g BRCA m) metastatic breast cancer (MBC)

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292

448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

Structural Phase Transitions and Superconductivity in Fe 1+δ Se 0.57 Te 0.43 at Ambient and Elevated Pressures

Progress in the Development of Heavy Metal-Free Quantum Dots for Electroluminescent Displays

Structural phase transitions and superconductivity in Fe(1+delta)Se0.57Te0.43 at ambient and elevated pressures

Major Threat to Malaria Control Programs by Plasmodium falciparum Lacking Histidine-Rich Protein 2, Eritrea

Suchergebnisse filtern